Article Text

Download PDFPDF
The Expression of Tumor-Derived and Stromal-Derived Matrix Metalloproteinase 2 Predicted Prognosis of Ovarian Cancer
  1. Ziyi Fu, MD*,
  2. Sujuan Xu, MD,
  3. Ye Xu, MD,
  4. Jiehua Ma, MD*,
  5. Jingyun Li, PhD* and
  6. Pengfei Xu, MD*
  1. *Nanjing Maternal and Child Health Institute;
  2. Department of Clinical Laboratory, Nanjing Maternal and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, China.
  1. Address correspondence and reprint requests to Pengfei Xu, Nanjing Maternal and Child Health Institute, Nanjing Maternal and Child Health Care Hospital, 123 MoChou Rd, Nanjing 210004, China. E-mail:


Objective To evaluate the association of tumor-derived matrix metalloproteinase 2 (MMP-2) and stromal-derived MMP-2 expression with the prognosis of patients with ovarian cancer, a meta-analysis study was performed, which was aimed to comprehensively review the evidence of MMP-2 as prognostic biomarkers in ovarian cancers.

Methods All relevant studies were searched in PubMed and Web of Science until May 30, 2014. Hazard ratios (HRs) with their 95% confidence intervals (CIs) were used to assess the association between MMP-2 expression (tumor-derived or stromal-derived) and prognosis of patients with ovarian cancer. Pooled odds ratios (ORs) and their 95% CIs were used to assess the correlation of MMP-2 expression with the clinicopathological features of patients with ovarian cancer.

Results A total of 965 patients in 8 studies were included in this analysis. Among them, tumor-derived and stromal-derived MMP-2 expression was detected in 7 and 5 articles, respectively. The results revealed that ovarian cancer patients with positive tumor-derived MMP-2 expression showed a worse prognosis than did the ones with negative tumor-derived MMP-2 expression (HR, 1.52; 95% CI, 1.06–2.20). However, ovarian cancer patients with positive stromal-derived MMP-2 expression had not. In addition, we also found that tumor-derived MMP-2 expression was associated with distant metastasis (absent vs present; pooled OR, 4.52; 95% CI, 1.56–13.09; P = 0.001).

Conclusions These results suggested that positive tumor-derived MMP-2 expression could predict a lower overall survival rate and could be an independent dangerous prognostic factor in patients with ovarian cancer.

  • Tumor-derived
  • Stromal-derived
  • MMP-2
  • Ovarian cancer
  • Prognosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Supported by the National Natural Science Foundation of China (No. 81402139) and the Key Program of Science and Technology Development Fund of Nanjing Medical University (No. 2013NJMU145).

  • The authors declare no conflicts of interest.

  • Authors Ziyi Fu and Sujuan Xu contributed equally to this work.

  • This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.